Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A multi-component combination of **isopropyl alcohol**, **bupivacaine**, and **dexamethasone**. - **Bupivacaine** is a long-acting local anesthetic that inhibits nerve impulse transmission by blocking voltage-gated sodium channels in neuronal membranes, resulting in analgesia and anesthesia. - **Dexamethasone** is a synthetic glucocorticoid with potent anti-inflammatory, immunosuppressive, and analgesic properties; when added to bupivacaine, it significantly prolongs the duration of peripheral nerve block analgesia and reduces postoperative opioid requirements through a perineural mechanism, likely involving vasoconstriction and direct action on peripheral glucocorticoid receptors[1][2][3][4][5]. - **Isopropyl alcohol** is an antiseptic agent, generally used for skin disinfection, not for analgesic or anesthetic effect. This combination may be used in perioperative settings for local/regional anesthesia to enhance analgesia duration, minimize opioid consumption, and prevent infection. No evidence of unique combination product or branded drug formulation of all three ingredients together is identified in the literature; the combination primarily reflects off-label or compounded clinical practice.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isopropyl alcohol + bupivacaine + dexamethasone.